Eric Lawrence Simpson MD

Associate Professor, Dermatology, Oregon Health and Science University School of Medicine

3181 SW Sam Jackson Park RdPortland, OR 97239
Phone+1 503-418-3376
Fax+1 503-494-6968

Dr. Simpson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Simpson's full profile Already have an account?

Education & Training

Oregon Health & Science University (OHSU Health)Residency, Dermatology, 1999 - 2002
Baylor University Medical CenterInternship, Internal Medicine, 1998 - 1999
University of Texas Southwestern Medical SchoolClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OR State Medical License 2002 - 2027
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Efalizumab for Moderate to Severe Atopic Dermatitis
COMPLETED
PHASE1
Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis
COMPLETED
PHASE4
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical tr...
Eric L Simpson, Vimal H Prajapati, Christopher G Bunick, Raj Chovatiya, Linda F Stein Gold
The Journal of Dermatological Treatment. 2026-12-01
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
Andrew Blauvelt, Eric L Simpson, Kilian Eyerich, Marjolein de Bruin-Weller, Sebastien Barbarot
The Journal of Dermatological Treatment. 2026-12-01
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.
Jonathan I Silverberg, Eric L Simpson, Saleem A Farooqui, Gary Chan, Pinaki Biswas
Dermatology and Therapy. 2026-08-01

Journal Articles

Efficacy and Safety of Baricitinib Combined with Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
Lawrence F Eichenfield, Eric L Simpson, JAMA Dermatology
Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis
Jonathan I Silverberg, Eric L Simpson, Hernan Valdez, JAMA Dermatology
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
Jonathan I Silverberg, Amy S Paller, Mark Boguniewicz, Sarah L Chamlin, Eric L Simpson, Lawrence F Eichenfield, Steven R Feldman, Dermatology and Therapy

Lectures

Atopic Dermatitis
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019

Authored Content

Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic DermatitisJune 2020

Press Mentions

Super Response to Biologics for Skin Diseases Often Predicts Sustained BenefitOctober 3rd, 2025
Will ROCKET Trials Put Atopic Dermatitis on New Trajectory?September 26th, 2025
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe EczemaOctober 4th, 2024

Grant Support

Parent-directed remote identification and severity assessments enabling decentralized trials in atopic dermatitisOREGON HEALTH & SCIENCE UNIVERSITY2024–2026
A Community-based Assessment of Skin Care, Allergies, and Eczema: The CASCADE TrialOREGON HEALTH & SCIENCE UNIVERSITY2018–2025
The Role Of The Skin Barrier In Atopic Dermatitis Development And PreventionNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2012